{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:45:03Z","timestamp":1768621503374,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,11,25]],"date-time":"2008-11-25T00:00:00Z","timestamp":1227571200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/s10067-008-1039-1","type":"journal-article","created":{"date-parts":[[2008,11,26]],"date-time":"2008-11-26T15:00:08Z","timestamp":1227711608000},"page":"321-326","source":"Crossref","is-referenced-by-count":11,"title":["Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study"],"prefix":"10.1007","volume":"28","author":[{"given":"Darko","family":"Kastelan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petar","family":"Lozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Stamenkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blazenka","family":"Miskic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonko","family":"Vlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeljka","family":"Kolak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasminka","family":"Milas Ahic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Velimir","family":"Altabas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeljka","family":"Crncevic Orlic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirko","family":"Korsic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,11,25]]},"reference":[{"key":"1039_CR1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J-Y Reginster","year":"2000","unstructured":"Reginster J-Y, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"1039_CR2","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized, controlled trial. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"1039_CR3","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut III","year":"2004","unstructured":"Chesnut CH III, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"1039_CR4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1185\/030079908X253717","volume":"24","author":"ST Harris","year":"2008","unstructured":"Harris ST, Blumentals WA, Miller PD (2008) Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 24:237\u2013245","journal-title":"Curr Med Res Opin"},{"key":"1039_CR5","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s10067-007-0824-6","volume":"27","author":"JA Stakkestad","year":"2008","unstructured":"Stakkestad JA, Lakatos P, Lorenc R et al (2008) Monthly oral ibandronate is effective and well tolerated after 3\u00a0years: the MOBILE long term extension. Clin Rheumatol 27:955\u2013960","journal-title":"Clin Rheumatol"},{"key":"1039_CR6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jbspin.2006.05.007","volume":"74","author":"E Lespessailles","year":"2007","unstructured":"Lespessailles E (2007) A forgotten challenge when treating osteoporosis: getting patients to take their meds. Jt Bone Spine 74:7\u20138","journal-title":"Jt Bone Spine"},{"key":"1039_CR7","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00198-003-1502-4","volume":"14","author":"RA Yood","year":"2003","unstructured":"Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965\u2013968","journal-title":"Osteoporos Int"},{"key":"1039_CR8","first-page":"408","volume":"72","author":"R Eastell","year":"2003","unstructured":"Eastell R, Garnero P, Vrijens B (2003) Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 72:408","journal-title":"Calcif Tissue Int"},{"key":"1039_CR9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","volume":"15","author":"JJ Caro","year":"2004","unstructured":"Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003\u20131008","journal-title":"Osteoporos Int"},{"key":"1039_CR10","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0149-2918(02)80085-6","volume":"24","author":"JA Simon","year":"2002","unstructured":"Simon JA, Lewiecki EM, Smith ME et al (2002) Patient preference for once-weekly alendronate 70\u00a0mg versus once-daily alendronate 10\u00a0mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24:1871\u20131886","journal-title":"Clin Ther"},{"issue":"Suppl 1","key":"1039_CR11","first-page":"SA407","volume":"19","author":"RR Recker","year":"2004","unstructured":"Recker RR, Gallagher R, Amonkar M et al (2004) Medication persistence is better with weekly bisphosphonates, but it remains suboptimal. J Bone Miner Res 19(Suppl 1):SA407","journal-title":"J Bone Miner Res"},{"key":"1039_CR12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.maturitas.2003.12.012","volume":"48","author":"D Kendler","year":"2004","unstructured":"Kendler D, Kung AW, Fuleihan Gel H et al (2004) Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48:243\u2013251","journal-title":"Maturitas"},{"key":"1039_CR13","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1185\/030079905X74862","volume":"21","author":"R Emkey","year":"2005","unstructured":"Emkey R, Koltun W, Beusterien K et al (2005) Patient preference for once monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Bonviva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895\u20131903","journal-title":"Curr Med Res Opin"},{"key":"1039_CR14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jbspin.2007.07.011","volume":"75","author":"P Hadji","year":"2008","unstructured":"Hadji P, Minne H, Pfeifer M et al (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Jt Bone Spine 75:303\u2013310","journal-title":"Jt Bone Spine"},{"key":"1039_CR15","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10067-007-0827-3","volume":"27","author":"S Grazio","year":"2008","unstructured":"Grazio S, Babic-Naglic D, Kehler T et al (2008) Persistence of weekly alendronate: a real-world study in Croatia. Clin Rheumatol 27:651\u2013653","journal-title":"Clin Rheumatol"},{"key":"1039_CR16","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1185\/030079906X154079","volume":"22","author":"R Keen","year":"2006","unstructured":"Keen R, Jodar E, Iolascon G et al (2006) European women\u2019s preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency. Curr Med Res Opin 22:2375\u20132381","journal-title":"Curr Med Res Opin"},{"key":"1039_CR17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1185\/030079906X104740","volume":"22","author":"TW Weiss","year":"2006","unstructured":"Weiss TW, Gold D, Silverman S et al (2006) An evaluation of patient preferences for osteoporosis medications and their attributes: results from the PREFER-US study. Curr Med Res Opin 22:949\u2013960","journal-title":"Curr Med Res Opin"},{"key":"1039_CR18","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s10067-008-0971-4","volume":"27","author":"D Kastelan","year":"2008","unstructured":"Kastelan D, Korsic M, Vlak T (2008) Ibandronate: is there an effect on nonvertebral fractures? Clin Rheumatol 27:1313\u20131315","journal-title":"Clin Rheumatol"},{"key":"1039_CR19","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1359\/jbmr.1997.12.3.456","volume":"12","author":"E Lydick","year":"1997","unstructured":"Lydick E, Zimmerman SI, Yawn B et al (1997) Development and validation of a discriminative quality of life questionnaire for osteoporosis (the OPTQoL). J Bone Miner Res 12:456\u2013463","journal-title":"J Bone Miner Res"},{"key":"1039_CR20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"The EruoQol Group","year":"1990","unstructured":"The EruoQol Group (1990) EuroQol\u2014a new facility for the measurement of health related quality of life. Health Policy 16:199\u2013208","journal-title":"Health Policy"},{"key":"1039_CR21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1477-7525-4-42","volume":"4","author":"EM Flood","year":"2006","unstructured":"Flood EM, Beusterien KM, Green H et al (2006) Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women. Health Qual Life Outcomes 4:42","journal-title":"Health Qual Life Outcomes"},{"issue":"Suppl 1","key":"1039_CR22","first-page":"S445","volume":"19","author":"RJ Sebaldt","year":"2004","unstructured":"Sebaldt RJ, Shane LG, Pham BZ et al (2004) impact on non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis treated in tertiary specialist care. J Bone Miner Res 19(Suppl 1):S445","journal-title":"J Bone Miner Res"},{"key":"1039_CR23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jbspin.2007.06.004","volume":"75","author":"FE Cotte","year":"2008","unstructured":"Cotte FE, Cortet B, Lafuma A et al (2008) A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France. Jt Bone Spine 75:201\u2013208","journal-title":"Jt Bone Spine"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-008-1039-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-008-1039-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-008-1039-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:51:32Z","timestamp":1559119892000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-008-1039-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,25]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["1039"],"URL":"https:\/\/doi.org\/10.1007\/s10067-008-1039-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,25]]}}}